High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL

Meeting coverage of the 2022 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies focused on a debate between Jeremy S. Abramson, MD, and Mazyar Shadman, MD, MPH, regarding the preferred second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): high-dose chemotherapy and autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T-cell therapy?